Intended for healthcare professionals

Practice Clinical updates

Diagnosis and management of postpartum haemorrhage

BMJ 2017; 358 doi: https://doi.org/10.1136/bmj.j3875 (Published 27 September 2017) Cite this as: BMJ 2017;358:j3875
cropped thumbnail of infographic

Infographic available

A visual summary of suggested approaches for the management of primary and secondary postpartum haemorrahage

Chitosan-covered gauzes for pressure therapy in postpartum haemorrhage

We welcome the review by Chandraharan and Krishna on the diagnostic and management of postpartum haemorrhage (PPH) [1]. We wish to comment on the role of pressure therapy with chitosan-covered gauzes, an innovative uterine packing technique in the management algorithm of PPH, not mentioned in the review.

Recent findings of the WOMAN study, a pragmatic randomised double-blind, placebo-controlled trial, support a reduction of mortality due to PPH in women treated with tranexamic acid, an antifibrinolytic agent, especially when it is given within three hours after childbirth [2]. No significant reduction of hysterectomy rates was observed. Based on these findings, the authors conclude that tranexamic acid, should be given as soon as possible after the onset of bleeding. However, the WOMAN trial was conducted in high-level facilities (i.e. secondary and tertiary hospitals) which have all access to intravenous uterotonics, blood transfusion, and second-line interventions (e.g. uterine balloon tamponade, arterial embolization, uterine compression sutures, or even hysterectomy) through escalation in a timely manner. This is not the case at home or in primary health care centres in low-resource settings where two thirds of childbirths, maternal near-miss events, and maternal deaths occur [3], despite improved education of the health care work force [4].

In this context, we regret the absence of clear information dedicated to health care workers in low-resource settings in the review of Chandraharan and Krishna [1]. Thus, in the management of the possible causes of PPH and the infographic summarizing their guidelines (http://bmj.com/content/bmj/suppl/2017/09/27/bmj.j3875.DC1/chae036081.wi.pdf), most of proposed interventions can be implemented only within high-level facility hospitals. The aim of PPH management in rural areas should be primarily to stop the bleeding to allow sufficient time to transport to hospital where more extensive treatment options are available.

In this context, chitosan-covered gauzes offer a ready-to-use solution that is easy to handle in the primary care setting [5-13]. Based on our collective experience in treating more than one hundred cases of severe PPH with chitosan-covered gauzes (CeloxTM) [5-8], we want to draw attention to this low-cost intervention and initiate further research in its use in PPH.

Chitosan is a hydrophilic polysaccharide made by deacetylation of chitin, the structural component of crustacean shells [5-9]. It has widespread applications and is highly biocompatible. Its haemostatic properties are independent of clotting cascades. Chitosan coagulates blood through electrostatic interactions with red blood cell membranes and it is bioactive even in the presence of heparin. Interestingly, it has also antibacterial properties that may reduce the risk of infection. Based on a strong experimental rationale, it has been used for years by the British and American armies to achieve rapid and efficient haemostasis onto the battlefield, to control bleeding from to gunshot wounds [9].

Furthermore, it has been used as lifesaving intervention in uncontrollable haemothorax after cardiothoracic surgery (e.g. dissection of left anterior coronary artery, subclavian wound by stabbing) [10], or as an adjunct to packing in uncontrollable pelvic haemorrhage secondary to penetrating trauma (e.g. transpelvic gunshot wound, bilateral lower limb amputations) [11].

In clinical studies, it has been proven effective against conventional pressure bandages in achieving haemostasis within five minutes and reducing blood losses among civilians treated for penetrating limb trauma [12]. Recently, the combined treatment with chitosan-based pads and a rotary compression device was shown to achieve local haemostasis after radial artery access more rapidly than rotary compression device alone for coronary angiography in a single-centre open-label randomized controlled trial [13]. Several other uses are currently developed, including the maintenance of haemostasis during surgical procedures, prevention of recalcitrant epistaxis, and different uses in nanomedicine. In all these different uses, the authors underscore the safety of chitosan-coated devices and the absence of side-effect.

To our knowledge, chitosan use for haemostasis exists in six different forms: granules (powder), gauzes, nasal plugs, gel, sponges, and pads. Interestingly, for obstetric care purposes, chitosan medical devices, are less expensive than Bakri intrauterine balloons [5-8].

Importantly, in a recent model of pregnant ewe delivered by caesarean section, chitosan-embedded mini-sponge dressing was shown to fil the uterine cavity and maintain contact pressure over 24 hours without causing adverse systemic or local tissue effects, which supports the potential use and safety of chitosan in the uterine cavity [14].

In PPH, CeloxTM gauzes have been used in the obstetric ward of the Mariankrankenhaus hospital in Hamburg, Germany, since 2011 [5,6]. Uterine packing with chitosan-covered gauzes was successful alone or together with uterotonics infusion, curettage, or uterine compression suture, in a wide range of aetiologies including uterine atony, abnormal placental insertion (e.g. accreta, percreta, or increta), heparin-related coagulopathy, and bleeding after curettage [6]. Chitosan-covered gauzes were removed from the uterine cavity after 24-36 hours without observed side-effect. Most importantly, after introduction of haemostatic dressings, the number of postpartum hysterectomies dropped significantly (0.18% before, 0.05% after, relative risk reduction 72%, P-value = 0.0183) [7]. The experience on the effectiveness and safety on CeloxTM is collected in an international registry [7]. Recently, chitosan as haemostatic has been successfully used in French Guiana in a massive hemoperitoneum after hysterectomy, multiple vaginal lacerations and another hemoperitoneum, the two latter being treated with chitosan granules [8]. In Reunion, it was used with success in an invasive molar pregnancy with massive bleeding (unpublished data).

In conclusion, given actual restrictions in the use of tranexamic acid and barriers to successful implementation of uterine balloon tamponade in low-resource settings [15], and given the low cost and easy use of chitosan-covered gauzes, we emphasise the role for chitosan haemostatic dressings in the management algorithm of PPH proposed by Chandraharan and Krishna. Aim for the future is to add more evidence to the role of chitosan-covered gauze in PPH and randomized clinical trials are underway [16,17].

Acknowledgments

The authors thank their colleagues for their support.

Conflict of interest

Dr Mohammed Khairy Ali is the recipient of a grant from Assiut University.

References

1. Chandraharan E, Krishna A. Diagnosis and management of postpartum haemorrhage. BMJ 2017; 358: j3875. http://dx.doi.org/10.1036/bmj.j3875. PMID:28954732.
2. WOMAN trial collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy and other morbidities in women with post-partum haemorrhage (WOMAN)/ an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 189: 2105-16. http://dx.doi.org/10.1016/S0140-6736(1).30638-4. PMID:28456509.
3. Goldenberg RL, Saleem S, Ali S, et al. Maternal near miss in low-resource areas. Int J Gynaecol Obstet 2017; 138: 347-55. http://dx.doi.org/10.1002/ijgo.12219. PMID:28513837.
4. Lassi ZS, Kumar R, Bhutta ZA. Community-based care to improve maternal, newborn and child health. In: Reproductive, maternal, newborn and child health disease control priorities, third edition (vol. 2) World Bank press, 2016: 419 pp. PMID:27227219.
5. Schmid BC, Rezniczek GA, Rolf N, Maul H. Postpartum hemorrhage use of hemostatic combat gauze. Am J Obstet Gynecol 2012; 206: e12-3. http://dx.doi.org/1016/j.ajog.2011.09.018. PMID:22011588.
6. Schmid BC, Rezniczek GA, Rolf N, Saade G, Gebauer G, Maul H. Uterine packing with chitosan-covered gauze for control of postpartum hemorrhage. Am J Obstet Gynecol 2013; 209: 225.e1-5. http://dx.doi.org/1016/j.ajog.2013.05.055. PMID:23727525.
7. van Beckerath AK, Maul H, Gebauer G, et al. Use of chitosan-covered gauze in 98 cases of severe postpartum haemorrhage- a multicentre registry analysis. Am J Obstet Gynecol 2016; 214: S269.e1-5. http://dx.doi.org/10.1016/j.ajog.2015.10.535.
8. Carles G, Dabiri C, Mchirgui A, et al. Uses of chitosan for treating different forms of serious obstetrics hemorrhages. J Gynecol Obstet Hum Reprod 2017 Aug 1. pii:S2468-7847(17)30158-7. http://dx.doi.org/1016/j.jogoh.2017.08.003. [Epub ahead of print]. PMID:28864269.
9. Bennett BL, Littlejohn LF, Kheirabaddi BS, et al. Management of external haemorrhage in tactical combat casualty care: chitosan-based hemostatic gauze dressings—TCCC guidelines-Change 13-05. J Spec Oper Med 2014; 14: 40-57. http://dx.doi.org/10.1016/j.ajog.2015.10.535. PMID:25344707.
10. Millner RWJ, Lockhart AS, Bird H, Alexiou C. A new hemostatic agent: initial life-saving experience with Celox (Chitosan) in cardiothoracic surgery. Ann Thorac Surg 2009; 87: e13-4. http://dx.doi.org/10.1016/j.athoracsur.2008.09.046. PMID:19161732.
11. Arul GS, Bowley DM, DiRusso S. The use of CeloxTM gauze as an adjunct to pelvic packing in otherwise uncontrollable pelvic haemorrhage secondary to penetrating trauma. J R Army Med Corps 2012; 158: 331-4. PMID:23402073.
12. Hatamabadi HR, Asayesh-Zarchi F, Kariman H, Arhami-Dolatabadi A, Tabatabaey A, Amini A. Celox-coated gauze for the treatment of civilian penetrating trauma: a randomized clinical trial. Trauma Mon 2015; 20: e23862. http://dx.doi.org/10.5812/traumamon.23862. PMID:25825701.
13. Kang SH, Han D, Kim S, et al. Hemostasis pad combined with compression device after transradial coronary procedures: a randomized controlled trial. PLoS One 2017; 12: e0181099. http://dx.doi.org/10.1371/journal.pone.0181099. PMID:28742134.
14. Rodriguez MI, Jensen JT, Gregory K, et al. A novel tamponade agent for management of postpartum haemorrhage: adaptation of the Xstat mini-sponge applicator for obstetric use. BMC Pregnancy Childbirth 2017; 17: 187. http://dx.doi.org/10.1186/s12884-017-1373-x. PMID:28610569.
15. Tindell K, Garfinke R, Abu-Haydar E, et al. Uterine balloon tamponade for the treatment of postpartum haemorrhage in resource-poor settings: a systematic review. BJOG 2013; 120: 5-14. http://dx.doi.org/10.1111/j.1471-0528.2012.03454x. PMID:22882240.
16. Ali MK. Uterine tamponade for treatment of primary postpartum haemorrhage. ClinicalTrials number: NCT02568657. https://clinicaltrials.gov/ct2/show/NCT02568657.
17. Guillermin P, Gindrey C, Gérardin P. Hémorragies du post-partum. Essai croisé de non-infériorité randomisé en cluster, pragmatique, multicentrique, comparant le pansement hémostatique au chitosan Celox versus le Ballon de Bakri dans les saignements resistant au sulprostone (HeLoHPP). http://dx.doi.org/10.10140/RG.2.13542.3208/1.

Competing interests: No competing interests

24 October 2017
Philippe Guillermin
gynaecologist-obstétrician
Anne-Karen von Beckerath, gynaecologist-obstétrician, Department of Obstetrics and Gynaecology, Mariankrankenhaus, Hamburg, Germany;Mohammed Khairy Ali, gynaecologist-obstétrician, Department of Obstetrics and Gynaecology, Woman’s health Hospital, Faculty of Medicine, Assiut University, Assiut, Egypt;Claude Gindrey, anesthesiologist, Department of Anesthesiology, CHU Réunion, Saint Denis, Reunion, France;Patrick Gérardin, perinatal epidemiologist, Department of Obstetrics and Gynaecology, Pôle Femme Mère Enfant, INSERM CIC1410 Clinical Epidemiology, CHU Réunion, Saint Pierre, Reunion, France;Gabriel Carles, gynaecologist-obstétrician, Department of Obstetrics and Gynaecology, Saint-Laurent Hospital, French Guiana, France;Bernd C Schmid, gynaecologist-obstétrician, Department of Gynaecological Oncology, Royal Hospital for Women, Randwick Australia.
Department of Obstetrics and Gynaecology, Pôle Femme Mère Enfant, CHU Réunion, Saint Pierre, Reunion, France;
Centre Hospitalier Universitaire Groupe Hospitalier Sud Réunion, Pôle Femme Mère Enfant Service de Gynécologie-Obstétrique BP 350, 97448 Saint Pierre Cedex, Reunion